Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells
J. Clin. Invest. Yoshiyuki Takahashi, et al. 118:1099 doi:10.1172/JCI34409 [Go to this article.]

Figure 1
Disease response and survival based on RCC histology (clear-cell RCC versus non-clear-cell RCC). (A) The cumulative incidence of disease response (combined complete and partial responses [CR + PR]) following nonmyeloablative allogeneic HSCT. Onset of disease regression was delayed a median 133 days (range, 30–287 days) following HSCT. (B) Disease responses (complete responses plus partial responses) were only observed in RCC patients with clear-cell histology (48% versus 0% cumulative incidence of a disease response; P = 0.0018). (C) Patients with clear-cell histology had longer survival after HSCT compared with those with non-clear-cell RCC (median survival, 525 versus 273 days; P = 0.003).